The evolutionary safety of mutagenic drugs should be assessed before drug approval.
Some drugs increase the mutation rate of their target pathogen, a potentially concerning mechanism as the pathogen might evolve faster toward an undesired phenotype. We suggest a four-step assessment of evolutionary safety for the approval of such treatments.
Main Authors: | Gabriela Lobinska, Vyacheslav Tretyachenko, Orna Dahan, Martin A Nowak, Yitzhak Pilpel |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2024-03-01
|
Series: | PLoS Biology |
Online Access: | https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.3002570&type=printable |
Similar Items
-
Biological causal links on physiological and evolutionary time scales
by: Amit Karmon, et al.
Published: (2016-04-01) -
Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity
by: Ikbel Hadj Hassine, et al.
Published: (2022-04-01) -
Correction: A spatial vaccination strategy to reduce the risk of vaccine-resistant variants.
by: Xiyun Zhang, et al.
Published: (2023-10-01) -
Correction: Functional Characterization of Variations on Regulatory Motifs.
by: Michal Lapidot, et al.
Published: (2008-06-01) -
Manipulation of the human tRNA pool reveals distinct tRNA sets that act in cellular proliferation or cell cycle arrest
by: Noa Aharon-Hefetz, et al.
Published: (2020-12-01)